Prelude Therapeutics (PRLD) Net Cash Flow (2019 - 2026)

Prelude Therapeutics has disclosed Net Cash Flow across 8 years of filings, most recently posting -$13.5 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$13.5 million, down 148.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.3 million (down 224.16% YoY), and the FY2025 annual result was $22.0 million, up 271.44% from the prior year.
• Net Cash Flow came in at -$13.5 million for Q1 2026 at Prelude Therapeutics, down from -$12.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $27.8 million in Q1 2025 to a low of -$21.4 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$584000.0 (2024), against an average of -$640058.8.
• Peak annual rise in Net Cash Flow reached 4859.42% in 2025, while the deepest fall reached 1016.12% in 2025.
• Prelude Therapeutics' Net Cash Flow stood at -$21.4 million in 2022, then jumped by 143.87% to $9.4 million in 2023, then sank by 85.74% to $1.3 million in 2024, then tumbled by 1016.12% to -$12.3 million in 2025, then dropped by 9.97% to -$13.5 million in 2026.
• The last three Net Cash Flow figures came in at -$13.5 million (Q1 2026), -$12.3 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.